The predictive power of serum κ/λ ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 1, 2005, Pages 32-37

  Bergón, Enrique ^a   Miravalles, Elena ^a   Bergón, Elena ^b   Miranda, Isabel ^a   Bergón, Marta ^c  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Monoclonal gammopathy of undetermined significance (MGUS); Multiple myeloma (MM); Predictive power; Serum ratio

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; M PROTEIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CALCULATION; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NEPHELOMETRY; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROTEIN ANALYSIS; RANK SUM TEST; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN M; LIKELIHOOD FUNCTIONS; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; MYELOMA PROTEINS; PLASMA CELLS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 14244269452     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2005.004     Document Type: Article

References (18)

1. Ucci G, Riccardi A, Luoni R, Ascari E. Presenting features of monoclonal gammopathies: an analysis of 684 newly diagnosed cases. J Intern Med 1993;234:165-73.
2. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997;97: 810-4.
3. Van de Donk N, De Weerdt O, Eureling M, Bloem A, Lokhorst H. Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors. Leuk Lymphoma 2001;42:609-18.
4. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749-57.
5. Durie BG. Staging and kinetics of multiple myeloma. Sem Oncol 1986;13:300-9.
6. Bergón E, García-Alonso L. Frecuencia de gammapatías monoclonales en una muestra no seleccionada. Quim Clin 1997;16:135-41.
7. Terpstra WE, Lokhorst HM, Blomjous F, Meuwissen TH, Dekker AW. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol 1992;82:46-9.
8. Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996;87:912-8.
9. Kyle RA. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
10. Pasqualetti P, Festuccia V, Collacciani A, Casale R. The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. Acta Haematol 1997;97:174-9.
11. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al. Prognostic factors for malignant transformation in monoclonal gammopathies of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002;20:1625-34.
12. Censo de población 1990. Avances de resultados. Madrid: Instituto Nacional de Estadística, 1991.
13. Memoria 1999-2000 del Área Sanitaria 10. Madrid, 2001.
14. Weissler AM. A perspective on standardizing the predictive power of non-invasive cardiovascular tests by likelihood ratio computation: 1. mathematical principles. Mayo Clin Proc 1999;74:1061-71.
15. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmocytoma. Implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am 1997;11:71-86.
16. Gregersen H, Mellemkjær L, Ibsen JS, Dahlerup JF, Thomassen L, Sørensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 2001;86:1172-9.
17. Weissler AM. A perspective on standardizing the predictive power of non-invasive cardiovascular tests by likelihood ratio computation: 2. Clinical applications. Mayo Clin Proc 1999;74:1072-87.
18. Annotation. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.